• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用嵌合抗原受体自然杀伤细胞（CAR NK细胞）靶向ROBO1以对抗卵巢癌原发肿瘤细胞和类器官的有前景的方法。

Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.

作者信息

Zhu Yan, Wang Luanhong, Jiang Biyu, Wang Yini, Wu Qing, Hong Sihua, Wang Xiaojing, Li Yuancheng, Guan Tian, Zeng Haoyu, Li Congzhu

机构信息

Department of Gynecological Oncology, Cancer Hospital of Shantou University Medical College, Shantou, Guangdong, China.

Department of Cancer Research, Guangdong Procapzoom Biosciences Co., Guangzhou, Guangdong, China.

出版信息

Future Sci OA. 2024 Jul 11;10(1):2340186. doi: 10.2144/fsoa-2023-0135. Epub 2024 Jul 29.

DOI:10.2144/fsoa-2023-0135
PMID:39069888
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11290772/
Abstract

This study aimed to explore using peripheral blood mononuclear cell (PBMC)-derived chimeric antigen receptor (CAR) NK cells targeting ROBO1 as a personalized medicine approach for ovarian cancer. A two-step strategy generated ROBO1-targeted CAR NK cells from PBMCs of ovarian cancer patients. Efficacy was evaluated using xCELLigence RTCA, CCK-8 and Live/Dead fluorescence assays. ROBO1-NK cells exhibited higher efficiency in eradicating primary ovarian cancer cells and lysing ovarian tumor organoids compared with primary NK cells without ROBO1-CAR modification. These findings highlight the potential of developing ROBO1-targeted CAR-NK cells from patients' PBMCs as a personalized treatment option for ovarian cancer.

摘要

本研究旨在探索利用靶向ROBO1的外周血单个核细胞（PBMC）来源的嵌合抗原受体（CAR）自然杀伤（NK）细胞作为卵巢癌的个性化治疗方法。采用两步策略从卵巢癌患者的PBMC中生成靶向ROBO1的CAR NK细胞。使用xCELLigence RTCA、CCK-8和活/死荧光测定法评估疗效。与未进行ROBO1-CAR修饰的原代NK细胞相比，ROBO1-NK细胞在根除原发性卵巢癌细胞和裂解卵巢肿瘤类器官方面表现出更高的效率。这些发现凸显了从患者PBMC中开发靶向ROBO1的CAR-NK细胞作为卵巢癌个性化治疗选择的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/0bd97a7564c3/IFSO_A_2340186_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/5514da02f41a/IFSO_A_2340186_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/d56432f2f0d2/IFSO_A_2340186_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/e09fbc2c97e3/IFSO_A_2340186_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/0bd97a7564c3/IFSO_A_2340186_F0004_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/5514da02f41a/IFSO_A_2340186_F0001_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/d56432f2f0d2/IFSO_A_2340186_F0002_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/e09fbc2c97e3/IFSO_A_2340186_F0003_C.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2e29/11290772/0bd97a7564c3/IFSO_A_2340186_F0004_C.jpg

相似文献

1
Promising approach for targeting ROBO1 with CAR NK cells to combat ovarian cancer primary tumor cells and organoids.用嵌合抗原受体自然杀伤细胞（CAR NK细胞）靶向ROBO1以对抗卵巢癌原发肿瘤细胞和类器官的有前景的方法。
Future Sci OA. 2024 Jul 11;10(1):2340186. doi: 10.2144/fsoa-2023-0135. Epub 2024 Jul 29.
2
NK-92MI Cells Engineered with Anti-claudin-6 Chimeric Antigen Receptors in Immunotherapy for Ovarian Cancer.嵌合抗原受体修饰的 NK-92MI 细胞在卵巢癌免疫治疗中的应用
Int J Biol Sci. 2024 Feb 11;20(5):1578-1601. doi: 10.7150/ijbs.88539. eCollection 2024.
3
[Killing effect of Robo1 targeted Chimeric Antigen Receptor modified NK92 cells against glioma and neuroblastoma cells].Robo1靶向嵌合抗原受体修饰的NK92细胞对胶质瘤和神经母细胞瘤细胞的杀伤作用
Zhonghua Yi Xue Za Zhi. 2018 Mar 20;98(11):860-866. doi: 10.3760/cma.j.issn.0376-2491.2018.11.014.
4
Robo1-specific CAR-NK Immunotherapy Enhances Efficacy of I Seed Brachytherapy in an Orthotopic Mouse Model of Human Pancreatic Carcinoma.机器人 1 特异性 CAR-NK 免疫疗法增强了 I 种子近距离放疗在人胰腺癌细胞原位模型中的疗效。
Anticancer Res. 2019 Nov;39(11):5919-5925. doi: 10.21873/anticanres.13796.
5
Use of chimeric antigen receptor NK-92 cells to target mesothelin in ovarian cancer.嵌合抗原受体 NK-92 细胞在卵巢癌中针对间皮素的应用。
Biochem Biophys Res Commun. 2020 Mar 26;524(1):96-102. doi: 10.1016/j.bbrc.2020.01.053. Epub 2020 Jan 22.
6
Improved Killing of Ovarian Cancer Stem Cells by Combining a Novel Chimeric Antigen Receptor-Based Immunotherapy and Chemotherapy.新型嵌合抗原受体免疫疗法联合化疗增强卵巢癌干细胞杀伤作用。
Hum Gene Ther. 2017 Oct;28(10):886-896. doi: 10.1089/hum.2017.168. Epub 2017 Aug 24.
7
Challenges in αCD38-chimeric antigen receptor (CAR)-expressing natural killer (NK) cell-based immunotherapy in multiple myeloma: Harnessing the CD38dim phenotype of cytokine-stimulated NK cells as a strategy to prevent fratricide.嵌合抗原受体（CAR）表达的自然杀伤（NK）细胞免疫疗法在多发性骨髓瘤中面临的挑战：利用细胞因子刺激的 NK 细胞的 CD38dim 表型作为防止自相残杀的策略。
Cytotherapy. 2023 Jul;25(7):763-772. doi: 10.1016/j.jcyt.2023.03.006. Epub 2023 Apr 11.
8
3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids.使用患者来源的结直肠癌细胞类器官的 CAR 介导的细胞毒性的 3D 模型。
EMBO J. 2019 Jun 17;38(12). doi: 10.15252/embj.2018100928. Epub 2019 Apr 29.
9
Development of CAR-NK Cells Targeting cSCC-Specific Antigens for Precision Immunotherapy.针对 cSCC 特异性抗原的 CAR-NK 细胞的开发用于精准免疫治疗。
Methods Mol Biol. 2024;2849:253-263. doi: 10.1007/7651_2023_509.
10
Chimeric antigen receptor (CAR) natural killer (NK)-cell therapy: leveraging the power of innate immunity.嵌合抗原受体 (CAR) 自然杀伤 (NK) 细胞疗法：利用先天免疫的力量。
Br J Haematol. 2021 Apr;193(2):216-230. doi: 10.1111/bjh.17186. Epub 2020 Nov 20.

引用本文的文献

1
Rendering NK Cells Antigen-Specific for the Therapy of Solid Tumours.使自然杀伤细胞对实体瘤治疗具有抗原特异性。
Int J Mol Sci. 2025 Jun 29;26(13):6290. doi: 10.3390/ijms26136290.
2
The Blood-Cerebrospinal Fluid Barrier Dysfunction in Brain Disorders and Stroke: Why, How, What For?脑疾病和中风中的血脑屏障功能障碍：为何、如何、有何用？
Neuromolecular Med. 2024 Sep 15;26(1):38. doi: 10.1007/s12017-024-08806-0.

本文引用的文献

1
Escape from NK cell tumor surveillance by NGFR-induced lipid remodeling in melanoma.黑色素瘤中 NGFR 诱导的脂质重塑导致逃避 NK 细胞肿瘤监视。
Sci Adv. 2023 Jan 13;9(2):eadc8825. doi: 10.1126/sciadv.adc8825.
2
Molecular Biomarkers for the Early Detection of Ovarian Cancer.用于卵巢癌早期检测的分子生物标志物。
Int J Mol Sci. 2022 Oct 10;23(19):12041. doi: 10.3390/ijms231912041.
3
Feeder-Cell-Free and Serum-Free Expansion of Natural Killer Cells Using Cloudz Microspheres, G-Rex6M, and Human Platelet Lysate.使用 Cloudz 微球、G-Rex6M 和人血小板裂解物无饲养细胞和无血清扩增自然杀伤细胞。
Front Immunol. 2022 Mar 7;13:803380. doi: 10.3389/fimmu.2022.803380. eCollection 2022.
4
Photonic crystal barcodes assembled from dendritic silica nanoparticles for the multiplex immunoassays of ovarian cancer biomarkers.由树枝状二氧化硅纳米粒子组装的光子晶体条码，用于卵巢癌生物标志物的多重免疫分析。
Anal Methods. 2022 Jan 20;14(3):298-305. doi: 10.1039/d1ay01658j.
5
Anti-Tumor Activity of Expanded PBMC-Derived NK Cells by Feeder-Free Protocol in Ovarian Cancer.无饲养层培养方案扩增的外周血单个核细胞来源的自然杀伤细胞对卵巢癌的抗肿瘤活性
Cancers (Basel). 2021 Nov 22;13(22):5866. doi: 10.3390/cancers13225866.
6
Protocol for establishing organoids from human ovarian cancer biopsies.从人卵巢癌活检组织中建立类器官的方案。
STAR Protoc. 2021 Mar 31;2(2):100429. doi: 10.1016/j.xpro.2021.100429. eCollection 2021 Jun 18.
7
NK/T cell ratios associate with interleukin-2 receptor alpha chain expression and shedding in multiple sclerosis.NK/T 细胞比值与多发性硬化症中白细胞介素-2 受体α链的表达和脱落相关。
J Neuroimmunol. 2021 Apr 15;353:577499. doi: 10.1016/j.jneuroim.2021.577499. Epub 2021 Jan 24.
8
Escape of tumor cells from the NK cell cytotoxic activity.肿瘤细胞逃避 NK 细胞细胞毒性。
J Leukoc Biol. 2020 Oct;108(4):1339-1360. doi: 10.1002/JLB.2MR0820-652R. Epub 2020 Sep 15.
9
Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors.嵌合抗原受体修饰的自然杀伤细胞在 CD19 阳性淋巴肿瘤中的应用。
N Engl J Med. 2020 Feb 6;382(6):545-553. doi: 10.1056/NEJMoa1910607.
10
Development of c‑MET‑specific chimeric antigen receptor‑engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells.靶向 c-MET 的嵌合抗原受体工程化自然杀伤细胞的构建及其对人肝癌 HepG2 细胞的杀伤作用。
Mol Med Rep. 2019 Sep;20(3):2823-2831. doi: 10.3892/mmr.2019.10529. Epub 2019 Jul 25.